Detail akcie REGENXBIO online

Business Summary: REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Regenxbio Inc revenues increased 4% to $114.4M. Net loss increased 4% to $67.3M. Revenues reflect License and royalty revenue increase of 3% to $108.9M, Service revenue increase of 13% to $5.5M. Higher net loss reflects clinical-stage biotechnology segment loss increase of 6% to $54.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.25816 to -$1.28768.